About Environmental Impact Acquisition Corp
Environmental Impact Acquisition Corp. is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York. Address: 535 Madison Avenue, New York, NY, United States, 10022
Environmental Impact Acquisition Corp News and around…
Latest news about Environmental Impact Acquisition Corp (ENVIU) common stock and company :
Environmental Impact Acquisition Corporation (NASDAQ: ENVI) ("ENVI"), a publicly-traded special purpose acquisition company, announced today that ENVI's definitive proxy statement/prospectus (the "Proxy Statement") relating to the previously announced business combination with GreenLight Biosciences, Inc. ("GreenLight"), a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, has been filed with the U.S. Securities and Exchange Commission (
A biotechnology firm that researches and manufactures ribonucleic acid, or RNA, for use in human and plant health is expanding its footprint in Research Triangle Park ahead of the expected approval of its first product and its entrance onto the public markets. Massachusetts-based GreenLight Biosciences started research and development in RTP for the plant health side of its business near the beginning of the Covid-19 pandemic. About two years later, the company is expanding into a facility that includes 40,000 square feet of lab and office space and 15,000 square feet of greenhouse space.
GreenLight Biosciences has partnered with the non-profit scientific research organization IAVI to work together on a Phase I clinical trial in Africa. IAVI and its partners were among the first to conduct HIV vaccine clinical trials in Africa, and since then, IAVI has sponsored more than 60 vaccine and biologics clinical trials in 13 countries. IAVI has built partnerships with centers of excellence for clinical research in five sub-Saharan African countries, and is developing vaccines and biolog
GreenLight Biosciences Inc., an RNA-focused biotech ("GreenLight"), and Environmental Impact Acquisition Corp. (Nasdaq: ENVI) today announced an expansion of its PIPE financing to an aggregate $124 million in gross proceeds. The expanded financing includes a $10 million strategic investment from Serum Life Sciences Ltd ("Serum Life Sciences"), a subsidiary of Serum Institute of India Pvt. Ltd. (the "Serum Institute").
GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board.
GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the opening of its manufacturing plant in Rochester, New York, Bloomberg reports.
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Golden Nugget Online Gaming, Inc. (NASDAQ: GNOG) Golden Nugget Online Gaming has agreed to merge
BALA CYNWYD, PA / ACCESSWIRE / August 10, 2021 / Access Wire/ - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Environmental Impact Acquisition Corp. ("Environmental Impact" or the "Company") (NASDAQ:ENVI) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which Environmental Impact, a special purpose acquisition company, will combine with Gree
GreenLight Biosciences Inc is combining with a special-purpose acquisition company to go public in a deal that values the RNA-technology firm at about $1.5 billion. GreenLight is merging with Environmental Impact Acquisition Corp (NASDAQ: ENVI), which is backed by investment bank Canaccord Genuity Group Inc. GreenLight's ribonucleic acid (RNA) platform has developed candidates for COVID-19, influenza, and earlier-stage programs in sickle cell disease. It is simultaneously working on RNA-based su
Every investor in Environmental Impact Acquisition Corp. ( NASDAQ:ENVI ) should be aware of the most powerful...